LKS治疗市场－全球产业规模、份额、趋势、机会和预测：按类型、治疗方法、诊断、最终用户、地区和竞争格局划分，2021-2031年

全球 LKS 治疗市场预计将从 2025 年的 23.8 亿美元成长到 2031 年的 38.9 亿美元，复合年增长率为 8.53%。

该市场采用多管齐下的治疗方法，结合抗癫痫药物、皮质类固醇和语言治疗，用于治疗儿童后天性癫痫性失语症。该领域的成长主要得益于先进基因诊断工具的日益普及，这些工具能够早期、准确地检测出疾病，以及强有力的监管奖励鼓励製药公司投资孤儿药研发。这些根本性驱动因素不仅影响药物使用率，也积极推动了专业治疗方案的开发，从而有效拓展了临床应用范围，并与一般市场形成差异化。

根据癫痫基金会2024年的数据，约20%被诊断患有兰道​​-克莱夫纳症候群的儿童携带GRIN2A基因突变，凸显了针对特定遗传病因制定精准医疗策略的迫切需求。阻碍市场成长的主要障碍是该疾病经常被误诊为自闭症或听力损失，导致必要的医疗干预措施严重延误，并对长期治疗效果产生负面影响。

市场驱动因素

对罕见儿童神经系统疾病研发投入的增加正在从根本上改变全球LKS治疗市场，使研究重点从频谱抗癫痫药物转向疾病修正治疗。这笔资金的涌入旨在阐明发育性癫痫脑病变的复杂遗传基础，从而开发出针对根本病因而非仅仅控制症状的治疗方法。疾病的高成本也为增加研发投入提供了经济基础。美国国立卫生研究院（NIH）在2024年报告称，未控制癫痫的年度直接医疗成本约为30,343美元，凸显了有效干预措施的商业性可行性。因此，像癫痫研究所这样的机构正在加强资助力度，以加速临床创新，在其2023-2024年度报告中，研究津贴投入超过200万英镑。

扩大孤儿药认定范围和监管激励措施是第二个关键驱动因素，它们降低了开发针对兰道-克莱夫纳综合征等小规模众患者群体治疗方法的商业性风险。监管机构透过提供税额扣抵、费用减免和延长市场独占期等激励措施，为製药公司创造了有利的环境。这种支持性框架已在罕见遗传疾病治疗方法开发平臺中取得了实际进展。例如，2024年10月，Bespoke Gene Therapy Company宣布，FDA已核准其五项实验性基因疗法「罕见儿童疾病」认定。这项重要进展不仅支持新候选治疗方法的疗效，也吸引了更多生物技术投资进入兰道-克莱夫纳症候群领域。

市场挑战

兰道-克莱夫纳症候群 (LKS) 的频繁误诊是全球 LKS 治疗市场成长的一大障碍。由于疾病的症状与泛自闭症障碍和听力障碍相似，许多儿童患者在接受准确评估之前，被迫长期接受无效治疗。这种诊断上的混乱导致相当一部分目标患者群体未得到治疗或用药不当，从而降低了某些抗癫痫药物和皮质类固醇疗法的即时商业性需求，并直接阻碍了市场扩张。

因此，由于潜在消费者在疾病早期关键阶段无法被识别，製药公司的收入基础受到限制。根据国际罕见疾病组织 (Rare Diseases International) 于 2024 年进行的一项大规模诊断路径研究，60% 的罕见疾病患者最初被误诊为其他生理或心理疾病。如此高的误诊率涵盖了广泛的罕见疾病领域，这表明由于系统性识别不足，某些 LKS 治疗市场可能远未发挥其应有的潜力。

市场趋势

在全球LKS治疗市场中，采用远距復健平台进行语言治疗正成为一项关键趋势，旨在满足后天性失语症患者对持续语言介入的迫切需求。这一转变克服了偏远地区专业言语治疗师短缺的问题，并实现了高频次的治疗，这对于语言恢復至关重要，而传统的面对面咨询往往难以实现。数位健康工具的整合使得持续监测认知进展和确保復健通讯协定的执行成为可能。美国医学会（AMA）2025年12月发布的报告也支持了这一趋势，该报告指出，32.2%的神经科每週超过20%的患者就诊是远端医疗进行的。

同时，静脉注射免疫球蛋白（IVIG）疗法的日益普及反映出临床治疗正转向积极的免疫调节疗法，以控制与此综合征相关的癫痫和认知功能下降。随着兰道-克莱夫纳症候群自体免疫病因的证据不断增多，临床医生越来越多地为对标准抗癫痫药物和皮质类固醇治疗无效的病例开立IVIG处方，以阻止持续性睡眠棘波和波（CSWS）的进展。这一趋势显着增加了神经病学领域对血浆衍生疗法的商业性需求。例如，武田药品工业株式会社在2025年5月报告称，其免疫球蛋白产品系列的收入同比增长17.6%，这证实了全球对这些免疫标靶治疗的依赖性日益增强。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球LKS治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（局部性发作、强直性发作、失张力性发作）
  • 治疗方法（抗惊厥药、皮质类固醇、静脉注射免疫球蛋白、手术、语言治疗、其他）
  • 透过诊断（脑电图（EEG）、磁振造影（MRI）、听力测试、基因检测、其他）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美LKS治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲LKS治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区LKS治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲LKS治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美LKS治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球LKS治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Abbott Laboratories Inc.
• Cipla Inc.
• Glenmark Pharmaceuticals Limited
• Mankind Pharma Limited
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global LKS Treatment Market is projected to expand from USD 2.38 Billion in 2025 to USD 3.89 Billion by 2031, registering a CAGR of 8.53%. This market comprises a multidisciplinary therapeutic approach utilizing anticonvulsant drugs, corticosteroids, and speech-language pathology to manage acquired epileptic aphasia in pediatric patients. The sector's growth is primarily fuelled by the rising availability of sophisticated genetic diagnostic tools, which enable earlier and more precise detection of the disorder, along with strong regulatory incentives that stimulate pharmaceutical investment in orphan drug research. These fundamental drivers actively promote the development of specialized therapeutic solutions, differentiating themselves from general market trends by effectively broadening the clinical scope rather than simply influencing utilization rates.

According to 2024 data from the Epilepsy Foundation, approximately 20% of children diagnosed with Landau-Kleffner Syndrome carry a mutation in the GRIN2A gene, highlighting the urgent need for precision medicine strategies tailored to specific genetic etiologies. A major obstacle hindering market growth is the frequent misidentification of the condition as autism or hearing loss, which results in considerable delays in administering necessary medical interventions and adversely affects long-term treatment outcomes.

Market Driver

Increasing research and development investment in rare pediatric neurology is fundamentally transforming the Global LKS Treatment Market, shifting the focus from broad-spectrum anticonvulsants to disease-modifying therapies. This influx of capital is dedicated to understanding the complex genetic foundations of developmental epileptic encephalopathies, enabling the creation of treatments that address root causes rather than merely managing symptoms. The economic rationale for this increased spending is supported by the high cost of the condition; the National Institutes of Health reported in 2024 that annual direct medical costs for uncontrolled epilepsy reached approximately $30,343, emphasizing the commercial viability of effective interventions. Consequently, organizations like the Epilepsy Research Institute are scaling up funding, having invested over £2 million in research grants in their 2023-24 Annual Review to accelerate clinical innovation.

The expansion of orphan drug designations and regulatory incentives acts as a second pivotal driver, mitigating the commercial risks associated with developing therapies for small patient populations like those with Landau-Kleffner Syndrome. Regulatory bodies are cultivating a favorable environment for pharmaceutical companies by offering benefits such as tax credits, fee waivers, and extended market exclusivity. This supportive framework is yielding tangible progress in the pipeline for rare genetic conditions. For instance, Global Genes reported in October 2024 that the FDA granted Rare Pediatric Disease designations to five experimental gene therapies under the Bespoke Gene Therapy Consortium, milestones that not only validate emerging candidates but also attract further biotechnology investment into the LKS sector.

Market Challenge

The frequent misdiagnosis of Landau-Kleffner Syndrome serves as a substantial impediment to the growth of the Global LKS Treatment Market. Because the disorder presents with symptoms mimicking autism spectrum disorder and hearing impairments, many pediatric patients undergo prolonged periods of ineffective management before receiving an accurate evaluation. This diagnostic confusion directly hampers market expansion by leaving a significant portion of the addressable patient population untreated or incorrectly medicated, thereby reducing the immediate commercial demand for specific anticonvulsant and corticosteroid therapies.

Consequently, pharmaceutical manufacturers face a restricted revenue base as potential consumers remain unidentified during the critical early stages of the disease. According to a major 2024 survey by Rare Diseases International regarding diagnostic journeys, 60% of individuals with rare diseases were initially misdiagnosed with a different physical or psychological condition. This high rate of error in the broader rare disease landscape suggests that the specific market for LKS treatments is likely operating well below its true potential capacity due to these systemic identification failures.

Market Trends

The adoption of tele-rehabilitation platforms for speech therapy is emerging as a critical trend in the Global LKS Treatment Market, addressing the urgent need for consistent linguistic intervention in patients with acquired aphasia. This shift helps overcome the scarcity of specialized speech-language pathologists in remote areas, allowing for the high-frequency therapy sessions essential for regaining language skills that are often logistically challenging with traditional in-person visits. The integration of digital health tools facilitates continuous monitoring of cognitive progress and ensures adherence to rehabilitation protocols, a trend supported by the American Medical Association's December 2025 report, which noted that 32.2% of neurologists conducted more than 20% of their weekly patient visits via telehealth.

Concurrently, the rising utilization of Intravenous Immunoglobulin (IVIG) therapies reflects a clinical pivot towards aggressive immunomodulation to manage the epileptic and cognitive regression associated with the syndrome. As evidence regarding the autoimmune etiology of Landau-Kleffner Syndrome grows, clinicians are increasingly prescribing IVIG for cases refractory to standard anticonvulsants and corticosteroids to halt the progression of continuous spike-and-wave during sleep (CSWS). This trend is substantially increasing the commercial demand for plasma-derived therapies within the broader neurology sector; for example, Takeda Pharmaceutical Company Limited reported in May 2025 that revenue for its immunoglobulin product portfolio grew by 17.6% year-over-year, underscoring the expanding global reliance on these immune-targeting interventions.

Key Market Players

• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Abbott Laboratories Inc.
• Cipla Inc.
• Glenmark Pharmaceuticals Limited
• Mankind Pharma Limited
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited

Report Scope

In this report, the Global LKS Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

LKS Treatment Market, By Type

• Focal Motor Seizures
• Tonic Seizures
• Atonic Seizures

LKS Treatment Market, By Treatment

• Anticonvulsant Drugs
• Corticosteroids
• Intravenous Immunoglobulins
• Surgery
• Speech Therapy
• Others

LKS Treatment Market, By Diagnosis

• Electroencephalogram (EEG)
• MRI
• Audiometry
• Genetic Testing
• Others

LKS Treatment Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

LKS Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global LKS Treatment Market.

Available Customizations:

Global LKS Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global LKS Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures)
  • 5.2.2. By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others)
  • 5.2.3. By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America LKS Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States LKS Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Diagnosis
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada LKS Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Diagnosis
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico LKS Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Diagnosis
      • 6.3.3.2.4. By End User

7. Europe LKS Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany LKS Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Diagnosis
      • 7.3.1.2.4. By End User
  • 7.3.2. France LKS Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Diagnosis
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom LKS Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Diagnosis
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy LKS Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Diagnosis
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain LKS Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Diagnosis
      • 7.3.5.2.4. By End User

8. Asia Pacific LKS Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China LKS Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Diagnosis
      • 8.3.1.2.4. By End User
  • 8.3.2. India LKS Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Diagnosis
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan LKS Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Diagnosis
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea LKS Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Diagnosis
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia LKS Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Diagnosis
      • 8.3.5.2.4. By End User

9. Middle East & Africa LKS Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia LKS Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Diagnosis
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE LKS Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Diagnosis
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa LKS Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Diagnosis
      • 9.3.3.2.4. By End User

10. South America LKS Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Diagnosis
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil LKS Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Diagnosis
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia LKS Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Diagnosis
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina LKS Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Diagnosis
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global LKS Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson & Johnson
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Pfizer Inc.
• 15.4. Teva Pharmaceutical Industries Ltd
• 15.5. Abbott Laboratories Inc.
• 15.6. Cipla Inc.
• 15.7. Glenmark Pharmaceuticals Limited
• 15.8. Mankind Pharma Limited
• 15.9. Novo Nordisk A/S
• 15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer